The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group of progressive lung diseases. An estimated 32 million people in the United States have COPD.

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...